BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is the most important oncogenic pathway in human cancers. Tumors leading mutations in the gene encoding for v-raf murine sarcoma vir...
Main Authors: | Fabiana Crispo, Tiziana Notarangelo, Michele Pietrafesa, Giacomo Lettini, Giovanni Storto, Alessandro Sgambato, Francesca Maddalena, Matteo Landriscina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/9/1388 |
Similar Items
-
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01) -
Prevalence of BRAF Mutation in Papillary Thyroid Cancer
by: Shatha Dmour, et al.
Published: (2016-12-01) -
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
by: Woon Won Kim, et al.
Published: (2018-01-01) -
Combined analysis of BRAF-gene mutation and galectin-3 expression in preoperative diagnostics of thyroid cancer
Published: (2011-06-01) -
The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis
by: Xin Li, et al.
Published: (2020-07-01)